The OncLive Insider app is live!CME Opportunities

The OncLive Insider app is live!CME Opportunities

View More Breast Cancer Lung Cancer Gastrointestinal Cancer Genitourinary Cancers Ovarian Cancer Prostate Cancer Melanoma & Skin Cancer MCL MPN CAR T-cell Therapy Chronic Lymphocytic Leukemia Gynecologic Oncology Hematologic Oncology Immuno-Oncology Multiple Myeloma Urothelial Cancer

Breast Cancer Lung Cancer Gastrointestinal Cancer Genitourinary Cancers Ovarian Cancer Prostate Cancer Melanoma & Skin Cancer MCL MPN CAR T-cell Therapy Chronic Lymphocytic Leukemia Gynecologic Oncology Hematologic Oncology Immuno-Oncology Multiple Myeloma Urothelial Cancer

All Oncology News

OncLive News Network®

Insights MedNews Week OncChats OncLive News Network®OncLive TV Peer Exchange Podcasts Rapid Readouts

Conference Coverage

Conference Listing

Conference Coverage Conference Listing

Giants of Cancer Care

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Giants of Cancer Care CME/CE Scientific Interchanges State of the Science Summit / IPC National Fellows Forum Webinars

Partners Publications

Consensus Viewpoints

Interactive Tools

Consensus Viewpoints OncLive App Interactive Tools Sponsored

Biomarker Consortium Subscribe

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

© 2025 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

The OncLive Insider app is live!
CME Opportunities

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

OncLive SOSS

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

Global Perspective: CDK4/6 Inhibitors in HR+ Breast Cancer

EP. 1: The Spectrum of HR+ Breast Cancer: Approaching Treatment

July 26th 2018

EP. 2: Selecting Therapy for HR+ Breast Cancer

July 26th 2018

EP. 3: Considering CDK4/6 Inhibitors in Advanced Breast Cancer

July 26th 2018

EP. 4: HR+ Breast Cancer: Differences Between CDK4/6 Inhibitors

July 26th 2018

EP. 5: HR+ Breast Cancer: Prognostic Subgroups in MONARCH Trials

July 26th 2018

EP. 6: HR+ Breast Cancer: Risk-Stratifying to CDK4/6 Inhibitors

July 26th 2018

EP. 7: HR+ Breast Cancer: CDK4/6 Inhibitors & Sites of Metastasis

July 26th 2018

EP. 8: HR+ Breast Cancer: Factors in Selecting a CDK4/6 Inhibitor

July 26th 2018

EP. 9: Optimizing CDK4/6 Inhibition in HR+ Breast Cancer

July 26th 2018

EP. 10: Abemaciclib Monotherapy's Role in HR+ Breast Cancer

July 26th 2018

<
1
2
>

x